Cohort - Minho Integrative Database (MIND)-Ageing - JPND Neurodegenerative Disease Research

Title of the cohort

Cohort – Minho Integrative Database (MIND)-Ageing

Acronym for cohort

MIND-Ageing

Name of Principal Investigator

Title	Full Professor
First name	Nuno
Last name	Sousa

Address of institution where award is held

Institution	Institution Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho
Street Address	Campus Gualtar
City	Braga
Postcode	4710-057

Country

Portugal

Website

http://www.icvs.uminho.pt/neurosciences/

Contact email

[email protected]

Funding source

European consortium project SWITCHBOX, supported by the European Commission.

1. The cohort includes, or expects to include, incidence of the following conditions

Alzheimer’s disease and other dementias
Neurodegenerative disease in general

When studies on the above condition(s) are expected to become possible

Already possible

2a. Stated aim of the cohort

Assessment of cognition, brain neuroimmaging and neuroendocrine function as well as risk factors for cardiovascular and kidney disorders; serum, blood cells and urine are being kept for a biobank.

2b. Features distinguishing this cohort from other population cohorts

Longitudinal studies. Aims to describe and associate main factors involved in healthy cognitive ageing, including socio-demographic factors such as education and social-inclusion.

3a. i) Number of publications that involve use of cohort to date

3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

Dowling NM, Hermann B, La Rue A, Sager MA. Department of Biostatistics & Medical Informatics, University of Wisconsin School of Medicine and Public Health, USA. Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer’s disease. Neuropsychology 2010, 24(6):742-56.

Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer’s Disease Neuroimaging Initiative. Aging and Dementia Imaging Research Laboratory, Department of Radiology, Mayo Clinic and Foundation, USA. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010, 75(2):143-51.

Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR Jr, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative. Department of Neurosciences, University of California San Diego, USA. Clinical Core of the Alzheimer’s Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010, 6(3):239-46.

3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort

1) Identification of denominators and / or biochemical markers of endocrine, metabolic and genetic factors of healthy aging in humans, along with an analysis of the structure and brain function (cognition);
2) Evaluation of the hypothesis that healthy aging is associated with effective adaptation to metabolic stress;
3) Evaluation of the hypothesis that the lack of insulin signaling in the brain, or its down-stream targets, may be responsible for inadequate endocrine and metabolic characteristics in non-healthy aging in humans;
4) Application of bio-mathematical modeling of integrated measures of homeostasis and brain structure and function in order to facilitate the forecasting of elements that contribute to healthy aging.

4a. Study criteria: age range of participants at recruitment

Age in years from:	55
To (‘until death’ if applicable):	until death

4b. Study criteria: inclusion criteria

Over 55 years old, absence of dementia and/or presence of disabling pathologies or disease, and ability to understand informed consent.

4c. Study criteria: exclusion criteria

Age below 55 years old, dementia and/or presence of disabling pathologies or disease, and inability to understand informed consent.

5. Size of the cohort (i.e. number of participants enrolled)

1,000 – 5,000 participants

6a. Measures used to characterise participants

Neurocognitive tests, neuroimaging, endocrine and metabolic measures.

6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

7. Study design

Longitudinal
Cross sectional survey

8. Cases matched by

Other health assessment (specify) / N/A
Socio-demographic background

9a. Does the study include a specialised subset of control participants

9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date

01-03-2011

10a. ii) Data collection end date

10a iii) Data collection for this study is

Data collection ongoing
Data analysis ongoing

10b. Plans to continue the cohort study beyond the current projected end date

Yes – funding applied for
Yes – intend to apply for funding

11. Data collected

Only through the study

12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

	Yes/No	% available
Data summarised in database	Yes
Database is web-based	Yes
Database on spreadsheet	Yes
Database is on paper	Yes
Other (specify)

Language used:

English and Portuguese

13b. Format and availability of data held as individual records

	Yes/No	% available
Data held as individual records	Yes	100
Data is web-based	Yes
Data held on computer based records	Yes	100
Data held on cards
Other (specify)

Language used:

English and Portuguese

14a. Are data available to other groups

14b. Access policy/mechanisms for access if data are available to other groups

15. Data sharing policy specified as a condition of use

No requirement to make data publicly available

16a. Are tissues/samples/DNA available to other groups

16b. i) Description of available tissues/samples/DNA

16b. ii) Form available tissues/samples/DNA are supplied in

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

17. Is information on biological characteristics available to other groups

Yes, for all the cohort